TORONTO, March 27 /CNW/ - IntelliPharmaCeutics Ltd. (Delaware) is pleased
to announce significant results from a recently completed pilot clinical trial
for its new abuse-resistant, alcohol-resistant once-a-day oral oxycodone
formulation by its operating company IntelliPharmaCeutics Corp. of Toronto
("IntelliPharmaCeutics" or the "Company"). The product is covered by pending
patent applications for its novel ReXista(TM) abuse and alcohol resistant drug
delivery technology. It is one of the Company's line of in-house analgesic
products in development for the management of moderate to severe chronic and
acute pain.
